216 related articles for article (PubMed ID: 25307519)
1. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.
Burke MJ; Ahern C; Weigel BJ; Poirier JT; Rudin CM; Chen Y; Cripe TP; Bernhardt MB; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):743-50. PubMed ID: 25307519
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
9. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
[TBL] [Abstract][Full Text] [Related]
11. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
Morton CL; Houghton PJ; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2010 Aug; 55(2):295-303. PubMed ID: 20582972
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.
Aquino VM; Weitman SD; Winick NJ; Blaney S; Furman WL; Kepner JL; Bonate P; Krailo M; Qu W; Bernstein M
J Clin Oncol; 2004 Apr; 22(8):1413-9. PubMed ID: 15084615
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
[TBL] [Abstract][Full Text] [Related]
18. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
Geller JI; Pressey JG; Smith MA; Kudgus RA; Cajaiba M; Reid JM; Hall D; Barkauskas DA; Voss SD; Cho SY; Berg SL; Dome JS; Fox E; Weigel BJ
Cancer; 2020 Dec; 126(24):5303-5310. PubMed ID: 32914879
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
Greengard E; Mosse YP; Liu X; Minard CG; Reid JM; Voss S; Wilner K; Fox E; Balis F; Blaney SM; Adamson PC; Weigel BJ
Cancer Chemother Pharmacol; 2020 Dec; 86(6):829-840. PubMed ID: 33095287
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
